Mark Bonyhadi
Director/Board Member at TC BIOPHARM (HOLDINGS) PLC
Net worth: - $ as of 2023-11-29
Profile
Mark Bonyhadi, Ph.D., joined Qiming US in 2018 following a 30+-year career focused on the development of commercially viable approaches for bringing cell therapies, gene-modified cell therapies, and regenerative medicine from the bench to the clinic and into commercial use.
Most recently, Mark held various senior leadership positions in research, process research sciences, and academic affairs at Juno Therapeutics (acquired by Celgene, which was later acquired by BMS).
Previously, Mark was Director of Global Business Development for Cell Therapy at Invitrogen (acquired by Thermo-Fisher).
Mark was responsible for identifying and implementing business opportunities aligned with the cellular medicine portfolio, including leading the launch of the Cell Therapy Systems (CTS™) product line and working with academia and industry to accelerate the development of novel cell and/or gene-based therapies.
Prior to that, Mark served as Director and later Vice President of Research at Xycte Therapies in Seattle, WA, after becoming Senior Scientist at SyStemix, a Palo Alto-based collaborative effort with Sandoz, which later merged with Ciba Geigy to become Novartis.
His work there focused on T cell aspects related to their HIV-1 hematopoietic stem cell gene-therapy approach for treating HIV-1 infections.
Mark completed his postdoctoral training at SyStemix with Dr. Mike McCune and Dr. Hideto Kaneshima studying HIV pathogenesis in the SCID-hu mouse model.
He is a former Chair of the Industry Liaison Committee for the American Society for Gene and Cell Therapy (ASGCT).
He is the inventor on 11 patents and an author on 40 publications.
Mark currently serves as a scientific advisory board member for Akron Biotech.
Mark received a B.A.
from Reed College, Portland, OR, and a Ph.D.
from the University of California Berkeley, where he studied T cell immunology in the lab of Nobel laureate, James P.
Allison.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-02-05 | 0 ( -.--% ) | - $ | 2023-11-29 |
Mark Bonyhadi active positions
Companies | Position | Start |
---|---|---|
TC BIOPHARM (HOLDINGS) PLC | Director/Board Member | 2022-02-21 |
Qiming US Ventures Management, LLC
Qiming US Ventures Management, LLC Investment ManagersFinance Qiming US Ventures Management LLC (Qiming Venture Partners) is a Venture Capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | 2018-11-30 |
Former positions of Mark Bonyhadi
Companies | Position | End |
---|---|---|
JUNO THERAPEUTICS INC | Corporate Officer/Principal | 2017-12-31 |
Life Technologies Ltd.
Life Technologies Ltd. BiotechnologyHealth Technology Life Technologies Ltd. engages in scientific and medical activities. The company was founded on May 13, 1983 and is headquartered in Paisley, the United Kingdom. | Corporate Officer/Principal | 2012-12-31 |
Xcyte Therapies, Inc. | Chief Tech/Sci/R&D Officer | 2006-03-29 |
Training of Mark Bonyhadi
The Reed Institute | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
TC BIOPHARM (HOLDINGS) PLC | Health Technology |
Private companies | 4 |
---|---|
Xcyte Therapies, Inc. | Health Technology |
Life Technologies Ltd.
Life Technologies Ltd. BiotechnologyHealth Technology Life Technologies Ltd. engages in scientific and medical activities. The company was founded on May 13, 1983 and is headquartered in Paisley, the United Kingdom. | Health Technology |
Juno Therapeutics, Inc.
Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Qiming US Ventures Management, LLC
Qiming US Ventures Management, LLC Investment ManagersFinance Qiming US Ventures Management LLC (Qiming Venture Partners) is a Venture Capital subsidiary of Qiming Venture Partners Ltd founded in 2017 by Mark D. McDade and Gary Edward Rieschel. The firm is headquartered in Cambridge, Massachusetts. | Finance |
- Stock Market
- Insiders
- Mark Bonyhadi